BioSpecifics Technologies
-
Malvern’s Endo to Acquire Local Company for $658 Million and Bring Its Cellulite-Fighting Drug to Market
Malvern-based Endo Pharmaceuticals has agreed to acquire BioSpecifics Technologies, a 20-year-old company based in Wilmington, for around $658 million, writes Joseph DiStefano for The Philadelphia…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
